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a b s t r a c t
Background: In settings where measles has been eliminated, vaccine-derived immunity may in theory
wane more rapidly due to a lack of immune boosting by circulating measles virus. We aimed to assess
whether measles vaccine effectiveness (VE) waned over time, and if so, whether differentially in
measles-eliminated and measles-endemic settings.
Methods: We performed a systematic literature review of studies that reported VE and time since vacci-
nation with measles-containing vaccine (MCV). We extracted information on case definition (clinical
symptoms and/or laboratory diagnosis), method of vaccination status ascertainment (medical record
or vaccine registry), as well as any biases which may have arisen from cold chain issues and a lack of
an age at first dose of MCV. We then used linear regression to evaluate VE as a function of age at first dose
of MCV and time since MCV.
Results: After screening 14,782 citations, we identified three full-text articles from measles-eliminated
settings and 33 articles from measles-endemic settings. In elimination settings, two-dose VE estimates
increased as age at first dose of MCV increased and decreased as time since MCV increased; however,
the small number of studies available limited interpretation. In measles-endemic settings, one-dose VE
increased by 1.5% (95% CI 0.5, 2.5) for every month increase in age at first dose of MCV. We found no evi-
dence of waning VE in endemic settings.
Conclusions: The paucity of data from measles-eliminated settings indicates that additional studies and
approaches (such as studies using proxies including laboratory correlates of protection) are needed to
answer the question of whether VE in measles-eliminated settings wanes. Age at first dose of MCV
was the most important factor in determining VE. More VE studies need to be conducted in elimination
settings, and standards should be developed for information collected and reported in such studies.
Crown Copyright  2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.vaccine.2019.10.090
0264-410X/Crown Copyright  2019 Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Dalla Lana School of Public Health, 155 College Street Room 500, Toronto, Ontario M5T 3M7, Canada.
E-mail address: natasha.crowcroft@utoronto.ca (N.S. Crowcroft).
Vaccine 38 (2020) 460–469
Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccine
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461
2.1. Study design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461
2.2. Literature search . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461
2.3. Study screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462
2.4. Data extraction, synthesis and risk of bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462
3. Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 463
3.1. Elimination settings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.1.1. VE estimates reported . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.1.2. Age at first dose of MCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.1.3. Time since first dose of MCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.1.4. Risk of bias and sensitivity analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.2. Endemic settings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.2.1. VE estimates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.2.2. Age at first dose of MCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
3.2.3. Time since first dose of MCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466
3.2.4. Risk of bias and sensitivity analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466
4. Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 467
5. Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468
Declaration of Competing Interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468
Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468
Appendix A. Supplementary material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468
1. Introduction
Measles elimination is defined as the absence of endemic
measles virus transmission in a defined geographical area for
12 months, in the presence of a well-performing surveillance sys-
tem [1,2]. An ambitious goal to eliminate measles by 2020 has
been set by the six World Health Organization (WHO) Regions
[1,3]. While several countries have eliminated measles, some have
subsequently lost this status, and measles is not currently elimi-
nated in any WHO Region [4]. Measles outbreaks are causing ongo-
ing concern in many countries worldwide, including the
Philippines [5], the Democratic Republic of the Congo [6], Ukraine,
France [7] and the United States (US) [8]; such outbreaks demon-
strate how challenging it is to control measles. The risk of importa-
tion of wild-type measles virus will likely continue for many years.
As a result, vaccine-derived immunity will need to be sustained to
protect those in eliminated settings.
Vaccine-derived antibodies are known to be less durable than
those derived from infection with wild-type measles virus [9–
12]. Levels of antibody induced by measles vaccination decrease
over time [13], and, in settings where measles has been eliminated,
could potentially wane more rapidly due to a lack of immune
boosting by circulating measles virus [11]. Conversely, studies
from areas that have sustained measles elimination indicate that
vaccination provides protection for at least several decades [14],
suggesting that if waning immunity ever becomes a public health
problem (i.e. leads to sustained transmission or large outbreaks
after measles virus introductions in which secondary vaccine fail-
ure plays a major role), it will emerge slowly over a long period
[9,11].
In this systematic review, we aimed to investigate whether
there is evidence that measles vaccine effectiveness (VE) wanes
over time. Our goal was to assess VE by time since measles vacci-
nation. We hypothesized there might be evidence of waning
immunity in measles-eliminated settings but little evidence in
measles-endemic settings. Furthermore, we hypothesized there
may be a difference in VE following one dose of MCV in comparison
to two doses of MCV.
2. Methods
2.1. Study design
We used a Population Intervention Comparison Outcome Study
framework to define our research question. Our population was
individuals 9 months of age; our intervention was administration
of measles-containing vaccine (MCV); our comparison was the
time since first and last MCV dose (or proxy); our outcome was
VE or vaccine efficacy measured by the development of clinical
measles, as diagnosed by symptoms and/or laboratory confirma-
tion; and our study designs included ecological, randomized con-
trolled trials (RCT), non-RCT, cohort, case-control, and outbreak
investigations (case series). Our complete study protocol, includ-
ing search and screening details, can be viewed on PROSPERO
(#CRD42018109248).
With increasing measles activity, we selected VE as our out-
come of interest because it is the primary measure of how well
the measles vaccine works.
2.2. Literature search
We devised a search strategy according to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [15], which comprised bibliographic database and grey
literature searches, citation scanning (snowballing) and expert
consultation.
We searched MEDLINE, Embase, Global Health, BIOSIS Previews
and Science Citation Index, and asked content experts to recom-
mend relevant articles. We placed no restriction on year, but
removed animal studies, conference abstracts/presentations, or
non-research articles.
To search grey literature, we utilized a variety of online cata-
logues and repositories, and web search engines. We considered
the first 100 results of each query for the most relevant
webpages.
Our search strategy is detailed in Supplementary
Materials 1.
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2.3. Study screening
We used DistillerSR software (Evidence Partners, Ottawa,
Ontario, Canada) throughout screening. Two independent review-
ers screened the titles and abstracts identified by the literature
search in singular. Reviewers pilot tested 100 titles and abstracts
to ensure compliance with the screening criteria. We included arti-
cles for full-text screening if they reported on VE or vaccine effi-
cacy in any context.
During full-text screening, we determined the measles-
eliminated or -endemic status from Regional Verification Commis-
sion reports on progress towards and achievement of measles
elimination and expert consultations. We included all countries
that adhered to the WHO definition of ‘‘eliminated” [1,2], regard-
less of how long the country had held the status. We screened all
full-text articles in duplicate with a third reviewer consulted for
conflicts. We calculated a Cohen’s Kappa for full-text screening
agreement between reviewers after the first 20 articles, and
reviewers discussed their understanding of the inclusion/exclusion
criteria if agreement was low (i.e. <0.7) prior to proceeding. We
excluded studies that related only to the following: failure of indi-
viduals to mount an immune response to MCV (primary vaccine
failure [16]); a non-generalizable population; vaccinations given
to infants <9 months of age; experimental or high-titre vaccines;
vaccines combined with immunoglobulin and/or vitamin A; vacci-
nation through any administration route other than subcutaneous
or intramuscular; age groups >10 years; results that were influ-
enced by a supplemental immunisation activity (SIA); lack of infor-
mation relevant to the research question; or in an unsupported
format or language (case studies, letters, conference abstracts/pre-
sentations, modelling studies, non-English). We snowballed and
excluded relevant studies which did not contain primary data.
For articles to pass full-text screening, we required them to
include VE or vaccine efficacy (overall or by age/age group), and
time between MCV and measles diagnoses.
2.4. Data extraction, synthesis and risk of bias
We used two independent reviewers to extract all data from eli-
gible studies including median age and/or age range of measles
diagnosis, method of vaccination status verification, age at MCV,
among others. Extracted ages at each dose of MCV were linked to
the method of vaccine status verification. We developed our data
extraction form a priori; the two reviewers pilot tested the first
two articles from measles-endemic settings, and consulted a third
reviewer for disagreements. When data on the age at first dose of
MCV was not included in an article, we attempted additional
research to supplement this information.
One reviewer performed a risk of bias assessment for each study
using an adapted Cochrane ROBINS-I tool [17,18]. We identified
three criteria that that could contribute to a high risk of bias: cold
chain issues identified in the paper; width of age groups10 years;
and an unclear (i.e. did not have an upper and/or a lower bound) or
absent age at first dose. We conducted sensitivity analyses for each
criterion, removing all of the articles at high risk of bias.
In endemic and eliminated settings, we plotted age at first dose
of MCV and time since first dose of MCV against VE estimates.
Median ages at diagnosis were used in analyses in measles-
eliminated settings, and age ranges in measles-endemic settings
due to data limitations.
Fig. 1. PRISMA diagram.
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In endemic settings, we evaluated whether VE was significantly
associated with age at first dose of MCV by linear regression anal-
ysis of all data and for the subgroups of individuals exposed to
measles at <5 years and 5 years of age. This age was used as a
cut-off to mitigate the large number of data points in individuals
<5 years and account for age as a potential confounding variable.
Data were weighted by study precision, calculated using the VE
confidence intervals (CI). Furthermore in endemic settings, we
evaluated whether time since first dose of MCV was significantly
associated with VE by linear regression using the following cate-
gories: less than one year; one to less than two years; two to less
than five years; five to <10 years; and 10 years. Because time
since first dose was provided as a range, it could not be treated
as a continuous predictor. We used the shortest time since first
dose category (varied for sensitivity analyses) as the referent cate-
gory in each model. For all models in endemic settings, we deter-
mined the best-fitting model by comparing linear regression to
Poisson and negative binomial, and evaluating Akaike & Bayesian
Information Criteria. Data were weighted by precision.
All analyses were performed in STATA v.12.1 (StataCorp, College
Station, Texas, US).
3. Results
Following the removal of duplicates and addition of five articles
from snowballing references, we screened 14,782 titles/abstracts
and grey-literature documents (Fig. 1). We identified 381 full-
text articles eligible for full-text screening. Of these, we excluded:
86 articles as they pertained only to vaccine failure (did not report
VE); 48 articles written in a language other than English (n = 39) or
the full-text was irretrievable (n = 9); and 42 articles because they
did not contain primary data.
Of the remaining 205 articles, 11 were in measles-eliminated
settings, and 194 in -endemic settings. From the 11 studies in
measles-eliminated settings, three met full-text inclusion criteria
(Fig. 1, Table S2). Of the 194 studies in measles-endemic settings,
33 met full-text inclusion criteria (Fig. 1, Table S2). Our Cohen’s
Kappa for full-text screening was 0.62.
There were three methods of vaccine status verification identi-
fied in the 36 included articles: medical record, vaccine registry,
and patient/parent account. A total of 18 studies utilised medical
records, 2 vaccine registries, and 3 patient/parent accounts. An
additional 7 studies used a combination of medical record and
Table 1
Articles selected for inclusion from measles-eliminated settings (N = 3).
Selected article Title Characteristic
Country Study
period
Setting Year of
elimination
Number of measles
cases in study
Median age at
exposure
De Serres et al. [19] Higher risk of measles when the first
dose of a 2-dose schedule is given at
12–14 versus 15 months of age
Canada 2011 School 1998* 110 15
Hahné et al. [20] Measles outbreak among previously
immunized healthcare workers, the
Netherlands, 2014
The Netherlands 2014 Community 2012y 8 27
Choe et al. [21] An outbreak of measles in a
University in Korea, 2014
Republic of Korea 2014 School 2006 85 20
* King et al. [32].
y WHO [33].
 Heywood et al. [34].
Fig. 2. Vaccine effectiveness by age at first dose of measles-containing vaccine in measles-eliminated settings. *Cases in Choe et al. [21] were vaccinated between 9
and 15 months (indicated as 9 months in the figure). Cases in Hahné et al. [20] were vaccinated at 14 months. Cases in De Serres et al. [19] were vaccinated at 12 months,
13–14 months, and 15 months (the latter indicated as 15 months in the figure).
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patient/parent account, 2 a combination of vaccine registry and
medical records, 3 were missing, and 1 other.
3.1. Elimination settings
Studies performed in elimination settings were De Serres et al.,
describing a 2011 measles outbreak in a Canadian secondary
school 13 years after measles elimination [19], Hahné et al.
describing a 2014 measles outbreak among healthcare workers in
the Netherlands two years following measles elimination [20],
and Choe et al. describing a 2014 measles outbreak in a university
in the Republic of Korea, eight years following measles elimination
[21] (Table 1).
3.1.1. VE estimates reported
De Serres et al. reported various VE estimates, including by
number of MCV doses and by age at first dose of MCV. In compar-
ison, Hahné et al. and Choe et al. calculated only a two-dose VE
estimate using a single age at first dose of MCV. Therefore, we
focused on two-dose VE estimates as the only estimate common
to all three articles. We used median age of diagnosis to measles
as this was common to all three articles.
The VE estimates were presented by both age at first dose of
MCV and age of diagnosis, and ranged between 52.0% and 98.8%.
De Serres et al. had the largest number of cases with 110 cases, fol-
lowed by Choe et al. with 85 cases and Hahné et al. with 8 cases
(Table 1).
3.1.2. Age at first dose of MCV
The study by De Serres et al. suggested a small but significant
increase in VE with increasing age of first dose of MCV (Fig. 2).
However, the other studies were not useful in confirming this rela-
tionship. Choe et al. did not report an age at first dose; however,
following additional online research, we found that the first dose
of MCV was administered in the Republic of Korea between nine
and 15 months prior to 1997 [22]. All individuals studied by Choe
et al. would have received their childhood vaccinations prior to
1997, and would therefore have received their first dose of MCV
within this range. Furthermore, the point estimate for Hahné
et al. was low with extremely wide confidence intervals (52%,
95% CI 207, 93).
3.1.3. Time since first dose of MCV
Two-dose VE decreased as time since first dose of MCV
increased (Fig. 3). The tight confidence intervals exhibited by De
Serres et al. were in concordance with the highest VE and shortest
time since MCV. Both Choe et al. and Hahné et al. demonstrated
wider confidence intervals with longer time since first MCV.
3.1.4. Risk of bias and sensitivity analyses
Although Choe et al. had broad width of age at diagnosis bands
and an absent age at first dose (Table S3), due to the small number
of papers we did not perform sensitivity analyses.
3.2. Endemic settings
The 33 studies included from endemic settings were published
between 1982 and 2018. From these, 10 articles were published in
Africa [23–32], nine from Europe [33–41], six from Asia [42–47],
six from Oceania [48–53] and two from North America [54,55]
(Table 2). The articles included an RCT (n = 1) [38] and studies
focussed on measles in communities (n = 22) [23–32,35,36,41–43
,45,46,50,52–54,55], schools (n = 9) [33–35,37,39,40,44,48,51], or
households (n = 2) [47,49]. One study was performed in both a
community and school [35], and was therefore treated as two
studies.
3.2.1. VE estimates
The majority of VE estimates reported were one-dose VE esti-
mates, with few two-dose and even fewer overall estimates pro-
vided. The one-dose estimates spanned from 26.0% to 100.0%
(Fig. 4), and two-dose from 93.0% to 100.0%.
The ages at first dose of MCV in the 33 selected articles ranged
between 9 months and >24 months. Case counts of measles varied
greatly between the studies, with VE estimates calculated from
eight to 10,285 cases. Fewmedian ages of diagnosis were reported;
Fig. 3. Vaccine effectiveness by the duration of time since the first dose of measles-containing vaccine in measles-eliminated settings. *Values have been rounded for Choe
et al. [21] and Hahné et al. [20].
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Table 2
Articles selected for inclusion from measles-endemic settings (N = 33).
Selected article Title Characteristic
Country of
study
Study
period
Study setting Number
of
measles
cases in
study
Age range
Barrabeig et al. [33] MMR vaccine effectiveness in an outbreak that
involved day-care and primary schools
Spain 2006–2007 Daycare/school 17 15 mo
Bhuniya et al. [42] Measles outbreak among the Dukpa tribe of
Buxa hills in West Bengal, India: epidemiology
and vaccine efficacy
India 2011 Community 68 9–59 mo
Cheah, Lane, and Passaris [48] Measles vaccine efficacy study in a Canberra
high school: A study following a measles
outbreak
Australia 1991 School 35 13–15 yrs
Fernandes and Gill [34] Prevention of measles: vaccine efficacy and
potential effectiveness of a vaccination
programme on entry to school
U.K. 1985 School 35 3–8 yrs
Guris et al. [49] Measles vaccine effectiveness and duration of
vaccine-induced immunity in the absence of
boosting from exposure to measles virus
Palau 1993 Households 8 10 yrs
Harrison and Durham [50] The 1991 measles epidemic: how effective is
the vaccine?
New Zealand 1991 Community 1–19 yrs
Hennessey et al. [35] Measles epidemic in Romania, 1996–1998:
Assessment of vaccine effectiveness by case-
cohort and cohort studies
Romania 1996–1998 Community/
school
312 9 mo – 15
yrs
Hull, Williams, and Oldfield [23] Measles mortality and vaccine efficacy in rural
west Africa
Gambia 1981 Community 9–47 mo
Hutchins et al. [54] Evaluation of an early two-dose measles
vaccination schedule
U.S. 1989–1996 Community 43 15–59 mo
Janaszek, Gay, and Gut [36] Measles vaccine efficacy during an epidemic in
1998 in the highly vaccinated population of
Poland
Poland 1998 Community 2255 1–28 yrs
John et al. [43] Two doses of measles vaccine: Are some states
in India ready for it
India 1999–2006 Community 129 1–19 yrs
Kaninda et al. [24] Measles vaccine effectiveness in standard and
early immunization strategies, Niger, 1995
Niger 1995 Community 9–59 mo
Kim et al. [47] Efficacy of measles vaccine during the 1993
measles epidemic in Korea
Republic of
Korea
1993 Households 16 1–5 yrs
Lamb [25] Epidemic measles in a highly immunized rural
west African (Gambian) village
Gambia 1984–1985 Community 32 1–9 yrs
Lyons, Jones, and Salmon [37] Successful control of a school based measles
outbreak by immunization
U.K. 1991 School 77 10–16 yrs
Mahomva, Moyo, and Mbengeranwa
[26]
Evaluation of a measles vaccine efficacy during
a measles outbreak in Mbare, City of Harare,
Zimbabwe
Zimbabwe 1996 Community 28 9–35 mo
Malfait et al. [27] Measles epidemic in the urban community of
Niamey: transmission patterns, vaccine
efficacy and immunization strategies, Niger,
1990 to 1991
Niger 1990–1991 Community 3583 9–59 mo
Marufu et al. [28] Questioning the level of efficacy of the measles
vaccine in use in Zimbabwe
Zimbabwe 1987–1989 Community 110 10–23 mo
McDonnell, Jorm, and Patel [51] Measles outbreak in western Sydney Australia 1993 School 38 5–9 yrs
McIntyre et al. [55] Measles and measles vaccine efficacy in a
remote island population
U.S. 1977–1978 Community 87 1–9 yrs
Mudzamiri et al. [29] Measles vaccine efficacy in Masvingo District,
Zimbabwe
Zimbabwe 1987–1994 Community 31 12–23 mo
Mupere et al. [30] Measles vaccination effectiveness among
children under 5 years of age in Kampala,
Uganda
Uganda 1999 Community 70 9–59 mo
Nsubuga et al. [31] Factors contributing to measles transmission
during an outbreak in Kamwenge District,
Western Uganda, April to August 2015
Uganda 2015 Community 41 9 mo – 52
yrs
Ong et al. [44] A 24-year review on the epidemiology and
control of measles in Singapore, 1981–2004
Singapore 2004 School 9 8–14 yrs
Pillsbury and Quinn [52] An assessment of measles vaccine
effectiveness, Australia, 2006–2012
Australia 2006–2012 Community 189 1–15 yrs
Puri et al. [45] Measles vaccine efficacy evaluated by case
reference technique
India Not
reported
Community 109 12–35 mo
Ramsay, Morratt, and O’Connor [38] Measles vaccine: a 27-year follow-up U.K. 1964–1990 Longitudinal
RCT
53 12–25 yrs
Schmid et al. [39] Measles outbreak linked to a minority group in
Austria, 2008
Austria 2008 School 150 5–20 yrs
(continued on next page)
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therefore, we were limited to using age-ranges in analyses. Lastly,
not every article contained a case count and/or confidence interval,
restricting the VE estimates included in syntheses.
3.2.2. Age at first dose of MCV
We observed a wide range of ages at first dose, spanning
from 6 to greater than 24 months (Fig. S1). Although we
included articles which contained ages at first dose less than
9 months, we only extracted information from 9 months and
onwards.
One-dose VE increased as age at first dose of MCV increased
(Fig. 4). The relationship between the two variables of interest
was statistically significant with an age at first dose coefficient of
0.015 (95% CI 0.005, 0.025), indicating an increase of 1.5% VE with
each increasing month of age at first dose of MCV. In subgroup
analyses, the findings were 0.014 (95% CI 0.008, 0.036) for the
<5 age group, and 0.007 (95% CI 0.027, 0.040) for the 5 age
group.
Analyses were also performed for two-dose VE estimates, where
available. Four studies and nine estimates were used to assess VE
by both age at first and second dose; these studies were conducted
in Romania [35], Australia [52], Ukraine [40], and Poland [36]. We
observed a significant increase in VE as age at first dose increased
[0.014 (95% CI 0.000, 0.027), p = 0.046], and a similar but non-
significant result as age at second dose increased [0.015 (95% CI
0.000, 0.029), p = 0.050].
3.2.3. Time since first dose of MCV
No clear pattern emerged for the relationship between VE and
time since first dose of MCV (Fig. S2). Of all the categorical compar-
isons, only the ‘‘5 to less than 10 years” time since first dose of MCV
category using <1 year as the referent was significant (Table S3).
We also performed time since first dose analyses for two-dose
VE estimates, where available. We used the category of ‘‘1 to less
than 10 years” as the referent, and observed non-significant differ-
ences for both the ‘‘10 to less than 20 years” category [0.4% (95% CI
Table 2 (continued)
Selected article Title Characteristic
Country of
study
Study
period
Study setting Number
of
measles
cases in
study
Age range
Sharma, Chawla, and Datta [46] Field evaluation of measles vaccine efficacy in
Najafgarh Zone of Delhi
India 1987 Community 12–35 mo
Sheppeard et al. [53] Vaccine failures and vaccine effectiveness in
children during measles outbreaks in New
South Wales, March-May 2006
Australia 2006 Community 25 1–7 yrs
Velicko et al. [40] Nationwide measles epidemic in Ukraine: the
effect of low vaccine effectiveness
Ukraine 2005–2006 School 15–29 yrs
Weekly Epidemiological Record [32] Expanded programme on immunization:
measles vaccine efficacy
Ivory Coast 1982 Community 68 24–25 mo
Weekly Epidemiological Record [41] Expanded programme on immunization:
measles vaccine efficacy
Poland 1984 Community 10,285 1–4 yrs
Blank cells represent missing or unclear values.
Fig. 4. Vaccine effectiveness by age at first dose of measles-containing vaccine in measles-endemic settings. Red line represents linear regression trend line. Circle sizes
correspond to precision (larger circles = higher precision). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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1.9%, 2.7%) and ‘‘20 years” category [5.2% (95% CI 13.4%,
3.1%)].
3.2.4. Risk of bias and sensitivity analyses
Only one article was affected by width of the age of diagnosis
band issues [33] (Table S4). We were therefore unable to perform
sensitivity analyses on this criterion. Nine articles stated there
were cold chain issues [26,28–30,40,42,46,48,55] and 20 had
unclear or absent data on age at first dose of MCV [23–26,30,32,3
4–36,38,41–46,50,51,54,55]. Sensitivity analyses were performed
on these criteria to assess whether age at first dose of MCV or time
since first dose of MCV trend significance changed following
removal of the affected articles (Tables S5 and S6). Neither crite-
rion changed the outcome of age at first dose of MCV or time since
first dose of MCV analyses; therefore, analyses proceeded with all
33 included articles.
4. Discussion
Our over-whelming finding is a lack of sufficient quality data to
ascertain whether measles vaccination-induced immunity wanes
in elimination settings. This is surprising given that measles immu-
nisation is recommended in every country, and measles elimina-
tion is a target in every WHO region [3].
In measles-eliminated settings, definitive conclusions cannot be
drawn from the small number of heterogeneous studies to assess
whether VE decreased with increasing time since MCV. In
measles-endemic settings we anticipated finding little evidence
of waning. Our results concurred with this hypothesis with one
exception, the time period from 5 to less than 10 years since
MCV administration.
Our initial hypothesis that waning would only be evident in
measles-eliminated settings, in which a large proportion of the
population is immune through vaccination was based on previous
studies demonstrating that antibody levels generated by MCV are
lower than those generated by infection, and decrease over time
[11,56]. We also hypothesized that antibody levels would wane
faster in elimination settings because of the lack of boosting by cir-
culating measles virus [14]. In countries such as the US, incidence
of measles had been low for a long time prior to measles elimina-
tion, so the vast majority of the population has not been exposed to
wild measles viruses for more than 30 years. Measles elimination
has, however, been sustained despite multiple introductions of
measles virus, demonstrating that vaccination provides robust pro-
tection for at least several decades [11]. Although it is possible that
waning immunity in vaccinated individuals may not lead to sub-
stantial future outbreaks, the question remains unanswered since
every country currently benefits from the immunity of older age
groups, which is naturally-acquired through past measles virus
infection. No country has yet experienced the epidemiologic situa-
tion of having an entire population immune only through immuni-
sation. Finland, which was the first country worldwide to achieve
measles elimination status in 1994, is likely the country with the
highest proportion of birth cohorts that were born in an elimina-
tion setting. Studies on this population have demonstrated the
effects of time and the potential for waning antibody levels [57,58].
Our results demonstrate that age at first dose of MCV may be
the most influential driver in determining VE, confirming previous
findings [19,59–62]. In both measles-endemic and eliminated set-
tings, we observed a trend of increasing VE with increasing age at
first dose of MCV. The timing of administration of the first dose of
MCV balances several considerations. If the first dose is adminis-
tered too early, immune responses can be blunted due to infant
immunologic immaturity and maternal antibody interference
[60]. However, if administered too late, infants can be placed at risk
of measles virus infection [63,64]. The age at first dose of MCV in
high burden settings is recommended by the WHO to be at
9 months, or possibly 6 months if an outbreak is occurring, to bal-
ance these factors [65]. In low burden settings, the first dose of
MCV is administered between 12 and 15 months, favouring a
higher seroconversion rate, but lengthening the duration of sus-
ceptibility to measles [65].
Most immunisation schedules now include a second dose of
MCV. The introduction of the second dose helps immunize those
with primary vaccine failure; however, immune boosting immedi-
ately following this dose may be short-lived [66]. The immune
response, and, by proxy, VE, heavily depend on the age at which
the first dose is administered. This latter finding is of great conse-
quence for global vaccination policy given that the Americas
achieved elimination by ensuring the first dose was given at
12 months but most of the world is giving the first dose at
9 months, and the most populous country in the world (China) is
giving it as young as 8 months [67].
This systematic review has several limitations. Because of lim-
ited resources, we only included English articles in the review.
However, our search did not reveal any non-English studies set
in elimination settings. The small number of articles in measles-
eliminated settings may simply reflect the small number of
measles cases in these settings. However, our search strategy
may also not have captured all existing data to address our
research question if we missed VE estimates from investigations
that were not published in peer-reviewed or grey literature. The
method of defining cases was only available at an aggregate level,
and could not be assessed at an individual level. It was also chal-
lenging to estimate waning VE amongst populations that have
been eliminated for long periods of time, as only one of our three
included studies in elimination settings was performed 10 years
post-elimination [19]. It was not easy to compare results in
measles-eliminated or –endemic settings because of great hetero-
geneity in setting, and data variability and gaps. Additionally, study
heterogeneity prevented us from assessing laboratory confirma-
tion in risk of bias analyses, due to the great spatial and temporal
variability across studies. Including a large percentage of observa-
tional studies in our review introduced a variety of potential
biases. We were unable to accurately assess exposure to measles
virus in countries which may have previously been classified as
eliminated, but subsequently lost their status. Misclassification of
measles diagnoses may have occurred, due to the fact not all stud-
ies included laboratory confirmation in their case definitions.
Lastly, non-differential misclassification of vaccination status
may have occurred if information was not directly mentioned in
the article, for example if an SIA was performed.
Given that the data in eliminated settings is exceedingly weak,
we strongly recommend that public health authorities conduct
more VE studies to monitor what happens as previously infected
older birth cohorts die, and community protection becomes
increasing reliant solely on immunisation. With this change in
cohorts, it is essential researchers conduct studies examining the
degree of waning and how quickly population antibody levels fall
in the absence of circulating measles to inform elimination efforts.
We also recommend development of a standardized approach to
collecting and reporting information in studies of VE. The critical
importance of age at first dose as a determinant of VE deserves
much more attention in the development of country, regional
and global strategies towards measles elimination and, ultimately,
measles eradication.
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